A Phase II Trial of Continuous-Infusion Recombinant Interleukin-2 in Patients with Advanced Renal Cell Carcinoma: A Southwest Oncology Group Study

Robert P. Whitehead; Michael K. Wolf; Dilip L. Solanki; George P. Hemstreet; Pasquale Benedetto; Stephen P. Richman; Robert C. Flanigan; E. David Crawford

doi:10.1097/00002371-199508000-00004

Back

A Phase II Trial of Continuous-Infusion Recombinant Interleukin-2 in Patients with Advanced Renal Cell Carcinoma: A Southwest Oncology Group Study

Journal article

Peer reviewed

A Phase II Trial of Continuous-Infusion Recombinant Interleukin-2 in Patients with Advanced Renal Cell Carcinoma: A Southwest Oncology Group Study

Robert P. Whitehead, Michael K. Wolf, Dilip L. Solanki, George P. Hemstreet, Pasquale Benedetto, Stephen P. Richman, Robert C. Flanigan and E. David Crawford

Journal of immunotherapy (1997), Vol.18(2), pp.104-114

08/01/1995

DOI: https://doi.org/10.1097/00002371-199508000-00004

PMID: 8574465

Metrics

1 Record Views

Details

Title: A Phase II Trial of Continuous-Infusion Recombinant Interleukin-2 in Patients with Advanced Renal Cell Carcinoma
Creators: Robert P. Whitehead - Texas Tech University Health Sciences Center
Michael K. Wolf
Dilip L. Solanki - University of Oklahoma
George P. Hemstreet - University of Oklahoma
Pasquale Benedetto
Stephen P. Richman
Robert C. Flanigan - Loyola University Chicago
E. David Crawford - University of Colorado Denver
Publication Details: Journal of immunotherapy (1997), Vol.18(2), pp.104-114
Identifiers: 991005969893902656
Academic Unit: Urology
Language: English
Resource Type: Journal article

A Phase II Trial of Continuous-Infusion Recombinant Interleukin-2 in Patients with Advanced Renal Cell Carcinoma: A Southwest Oncology Group Study

Related links

Metrics

Details